FTSE 100 movers: Anglo surges as miners rise
4th Feb 2016 14:22
(ShareCast News) - The FTSE 100 had turned things around on Thursday, with the blue chip market in the green by mid-afternoon for the first time this week, up 33.66 points (0.58%) to 5,870.80. Miners were the biggest risers of the day as commodity prices rose as well as Asian stocks. Anglo American,
Read moreAstraZeneca warns of declining profits in 2016
4th Feb 2016 07:30
(ShareCast News) - Astrazeneca's shares dropped on Thursday after warning that the expiry of the patent on its anti-cholesterol drug Crestor will cut its profits this year on competition from cheaper generic versions. The FTSE 100 company said it sees a low to mid single-digit percentage decline
Read moreAstraZeneca wins EU approval for lung cancer drug Tagrisso
3rd Feb 2016 07:08
(ShareCast News) - AstraZeneca has won European regulatory approval to market its Tagrisso-branded tablets for the treatment of adult patients with certain forms of lung cancer. Tagrisso, which becomes the first new medicine to be approved under the European Commission's expedited process, will be a
Read moreAstraZeneca prostate cancer therapy reaches major milestone
28th Jan 2016 07:32
(ShareCast News) - One of AstraZeneca's cancer therapies reached a new milestone on Thursday, with the US Federal Drug Administration granting Lynparza a Breakthrough Therapy designation (BTD) for the treatment of a certain strain of prostate cancer. The FTSE 100 pharmaceutical firm said the Breakth
Read moreGSK, AstraZeneca and J&J join forces with universities for tech transfer fund
25th Jan 2016 15:21
(ShareCast News) - AstraZeneca, GlaxoSmithKline and Johnson & Johnson and three leading UK universities are joining forces to try to significantly improve the speed that academic scientific research is translated into new medicines. The University of Cambridge, Imperial College London and University
Read moreLondon close: Homebuilders lead bounce after Carney's remarks
19th Jan 2016 16:15
(ShareCast News) - Equities bounced back on Tuesday as a slowdown in Chinese economic growth fuelled stimulus hopes in Asia's largest economy and following 'dovish' remarks from the Governor of the Bank of England. The Footsie finished 96.88 points or 1.68% higher at 5,876.80 points, while the secon
Read moreBroker tips: AstraZeneca, BAE Systems, Unilever
19th Jan 2016 10:57
(ShareCast News) - Barclays upgraded AstraZeneca to 'equalweight' from 'underweight' and lifted the price target to 5,000p from 4,400p following a review of the pipeline and the recent Acerta Pharma and ZS Pharma deals. It said the upgrade reflected "an attractive growth outlook balanced by the pote
Read moreBarclays upgrades AstraZeneca on attractive growth outlook
19th Jan 2016 08:55
(ShareCast News) - Barclays upgraded AstraZeneca to 'equalweight' from 'underweight' and lifted the price target to 5,000p from 4,400p following a review of the pipeline and the recent Acerta Pharma and ZS Pharma deals. It said the upgrade reflected "an attractive growth outlook balanced by the pote
Read moreHSBC lifts AstraZeneca target price on haematological cancer forecasts
4th Jan 2016 13:01
(ShareCast News) - HSBC has hiked its target price for AstraZeneca shares after the pharmaceutical giant's acquisition of cancer specialist Acerta Pharma a week before Christmas. AstraZeneca revealed it had agreed to acquire a 55% stake in privately-owned Acerta for $2.5bn, with another $1.5bn due u
Read moreAstraZeneca gout treatment gets FDA approval
23rd Dec 2015 07:12
(ShareCast News) - AstraZeneca said its Zurampic drug, used to treat gout, had received approval from the US Food and Drug Adminstration. Zurampic, also known as Lesinurad, is used in combination with another type of drug that reduces production of uric acid in the body. Sean Bohen, Executive Vice
Read moreNew drug trial data supports AstraZeneca's clinical activity
18th Dec 2015 07:52
(ShareCast News) - AstraZeneca said on Friday that preliminary findings from the ATLANTIC trial of durvalumab, a treatment for a type of non-small cell lung cancer, supports the treatment's clinical activity. The FTSE 100 company said the treatment demonstrated clinical activity and durable response
Read moreThursday newspaper share tips: Dixons Carphone has long-term potential
17th Dec 2015 10:48
(ShareCast News) - Investing in Dixons Carphone is a good long term plan, according to The Times' Tempus. The FTSE 100-listed electronics and travel retailer saw like-for-like revenue rise 5% over the period, to £4.39bn. Its proforma headline profit before tax was also up, 23% to $121m, with statut
Read moreAstraZeneca buys majority stake in Acerta Pharma to expand oncology portfolio
17th Dec 2015 07:08
(ShareCast News) - AstraZeneca has announced it will acquire a 55% stake in Acerta Pharma over its oncology treatment - a deal valued at $4bn (£2.7bn). The deal will give the FTSE 100 pharmaceutical company access to the privately-owned US and Netherlands based biopharmaceutical company's acalabruti
Read moreAstraZeneca to acquire Takeda Pharmaceutical Company for drug rights
16th Dec 2015 07:48
(ShareCast News) - AstraZeneca will acquire the core respiratory business of Takeda Pharmaceutical Company for $575m (£382m). The deal includes the expansion of rights to chronic obstructive pulmonary disease (COPD) treatment roflumilast, also known as Daliresp in the US and Daxas elsewhere. The FT
Read moreAstrazeneca completes disposal of Entocort
15th Dec 2015 15:20
(ShareCast News) - AstraZeneca has received a $380m payment from Irish competitor Perrigo as the FTSE 100 company completed the disposal of right for a Crohn's disease medicine. Perrigo last month agreed to buy the US rights from AstraZeneca to sell Entocort capsules and generic Entocort capsules ma
Read more